Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVM-101
- Development stage
- Unknown
- Lead developer
- Enveric Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**EVM-101** is Enveric Biosciences' first-generation oral psilocybin drug candidate that was being developed with the University of Calgary's Hotchkiss Brain Institute for **Cancer Related Distress** in oncology patients. Publicly available sources describe it as a **psilocybin-based psychedelic small-molecule therapy**, intended to improve core symptoms of cancer-related psychological distress such as anxiety, depressed mood, demoralization, and stress-associated manifestations. Enveric later stated that the original EVM101 classic psilocybin program had been **discontinued** as the company prioritized newer psilocybin-derived programs.
- Other names
- first-generation oral psilocybinclassic psilocybin
Beyond the preview
Go deeper on EVM-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVM-101.